Multi-omics-based molecular classification of adrenocortical carcinoma predicts response to immunotherapy and targeted treatments.

ABSTRACT: Adrenal cortical carcinoma (ACC) is a rare and highly aggressive malignant tumor with dismal outcomes. Once metastasis occurs, the 5-year survival rate falls below 15%. Current treatment options offer LIMited benefit for advanced disease, Largely due to the absence of well-defined therapeutic targets, and there is an urgent need to develop new molecular classifications to achieve precise treatment strategies. In this study, we integrated multi-omics data including transcriptome, epigenetic, and genomic variation profiles and applied 10 clustering algorithms, identifying two robust molecular subtypes of ACC: Multi-Omics ACC Consensus Subtyping (MACCS)1 and MACCS2. Biologically, MACCS1 exhibits a proliferation-driven phenotype, whereas MACCS2 displays an immune activation state. Drug sensiti

SUBMITTER: Jin X 

PROVIDER: S-EPMC12491137 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature